The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.
Astrofame on MSN5h
Cancer: Your career horoscope - March 22Cancer: here are your career predictions for the day March 22 ...
Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...
LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
A 46-year-old woman was admitted to Sassoon General Hospital (SGH) three weeks ago after complaining of abdominal pain. Upon ...
The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...
GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable Stage II-IVA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback